Use of Chemotherapy and Androgen Signaling-targeted Inhibitors in Patients with Metastatic Prostate Cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 33218827.
- Also identified by DOI 10.1016/j.eururo.2020.10.016.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The recent CARD study has shown that sequential use of androgen receptor (AR)-targeted therapies is associated with worse outcomes when compared with cabazitaxel chemotherapy. Here we argue that this accounts for the majority of patients previously treated with an AR-targeted agent.
Medical subject headings
- Androgen Antagonists
- Antineoplastic Agents
- Prostatic Neoplasms, Castration-Resistant